Stories

Thu, 22 Oct 2026

Thu, 22 Oct 2026 L'Oreal says weight loss drugs are impacting beauty and skin care sales

The beauty giant's CEO says the use of GLP-1s is "a very important phenomenon for us".

* Sales at beauty giant L'Oreal rose by 7.7% in the three months to September, above analyst expectations.
* The company's head Nicolas Hieronimus attributed the growth to the increasing use of weight loss drugs known as GLP-1s.
* L'Oreal has seen a significant impact on beauty consumption and skin care consumption due to the rise in popularity of GLP-1s.
* The company has developed products, such as SkinCeuticals and Kiehl's, that target the side effects of rapid weight loss, including loose skin.
* In 2022, L'Oreal increased its stake in dermatology firm Galderma to 20%.
* Galderma has been conducting clinical trials on GLP-1 users concerned about loose skin.
* A survey by Galderma found that most weight loss medication users noticed changes to their facial appearance after using those drugs.